Statistics from Altmetric.com
The current landscape of breast density notification
Breast density is one of a number of independent risk factors for breast cancer.1 Having dense breasts (heterogeneously dense or extremely dense) is prevalent in 40%–50% of women in the breast screening population,2 making it one of the most common risk factors for breast cancer. Separate from this, having dense breasts also increases a woman’s risk of having a breast cancer missed on mammography, meaning that it increases the risk of having an interval cancer diagnosed before the next scheduled mammogram in screening participants.3 This is due to the lower sensitivity of mammography in women with dense breast tissue.4
Over the past decade, breast density has been a major topic of international discussion among women, physicians and policy-makers as a way to manage the risk of breast cancer.5 In the USA, unprecedented legislation has been enacted in 38 states and the District of Columbia to notify women about their breast density. Following on from this, in early 2019, the US Congress passed national breast density legislation which proposes that the US Food and Drug Administration ensures that all mammography facilities include breast density information in reports sent to patients and their physicians.6 This legislation has been driven by complex social phenomena, largely stemming from industry interest, consumer advocacy groups demanding that women be informed and concerns about the burden of missed cancers.5 7
However, it could be argued that legislation to enforce notification of breast density before protocols for its management exist, neglects the fundamental premise of evidence-based medicine. The current evidence to support widespread breast density notification at a population level is still lacking and the balance between the benefits and …
Contributors BN drafted the manuscript. All authors critically reviewed, contributed to and approved the manuscript.
Funding JH is supported by a NHMRC Early Career Fellowship (1112509). KM is supported by a NHMRC Principal Research Fellowship (1121110). NH is supported by a NBCF Breast Cancer Research Leadership Fellowship.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.